Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.

Date publication

juillet 2018

Journal

European journal of internal medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine , Pr BONNOTTE Bernard , Pr LOFFROY Romaric , Dr DEVILLIERS Hervé

Tous les auteurs :
Samson M, Devilliers H, Ly KH, Maurier F, Bienvenu B, Terrier B, Charles P, Guillevin L, Besancenot JF, Liozon E, Fauchais AL, Loffroy R, Binquet C, Audia S, Seror R, Mariette X, Bonnotte B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30054122

Résumé

The aim of this study was to evaluate tocilizumab (TCZ) as an add-on therapy to glucocorticoids (GC) during the first 3 months of treatment of giant cell arteritis (GCA).

Mots clés

Aortitis, Clinical trial, Giant cell arteritis, Relapse, Tocilizumab

Référence

Eur. J. Intern. Med.. 2018 Jul 24;: